The downregulation of PTPIP51 in combination with the high phosphorylation of the Tyr176 residue depicts a potential inhibition of the MAPK stimulating effect of PTPIP51 in breast cancer cells. The gene discussed is RMDN3; the disease is breast carcinoma.